Jawad Qureshi, MD
Ophthalmology · Southlake, TXNPI 1811926769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,027 of the $4,380 with a category attached, or 69.1%. 18 manufacturers reported payments, led by Penumbra, Inc. at 37.7% of the total. Reporting peaked in 2021 at $1,903 and has fallen 52.2% since, to $910 in 2025.
Across 85 payments — averaging $51.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$762
- AbbVie$334
- Apellis Pharmaceuticals, Inc.$334
- Medtronic$256
- Genentech USA, Inc.$209
- plus $835 from 12 others
Across 152 payments — averaging $12,643 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.4M
- Novartis$356K
- AstraZeneca$95K
- Ocular Therapeutix, Inc.$51K
- Regeneron$39K
- Astellas Pharma Global Development$11K
- plus $10K from 3 others
What the payments were for
- Travel & lodging$1,08325%
- Food & beverage$3,02769%
- Education$2716%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 4 | $1,650 |
| Regeneron Healthcare Solutions, Inc. | 24 | $762 |
| AbbVie(2 entities) | 11 | $334 |
| Apellis Pharmaceuticals, Inc. | 12 | $334 |
| Medtronic | 1 | $256 |
| Genentech USA, Inc. | 8 | $209 |
| Astellas Pharma US Inc | 10 | $202 |
| Abbott | 1 | $145 |
| Kala Pharmaceuticals, Inc. | 1 | $110 |
| Genentech, Inc. | 2 | $108 |
| Sandoz | 3 | $72 |
| Biotissue Holdings Inc. | 1 | $46 |
| Novartis | 2 | $39 |
| Alimera Sciences, Inc. | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $27 |
| Eyepoint US, Inc. | 1 | $24 |
| Notal Vision, Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,632
- MVP$256
- Perclose ProGlide suture mediated closure system$145
- OZURDEX$110
- INVELTYS$110
How this compares
$4,380 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 71 | $29,464 |
| Prednisolone Acetate | 164 | $6,605 |
| MoxifloxacinMoxifloxacin Hcl | 168 | $4,109 |
| Ketorolac Tromethamine | 159 | $3,842 |
| Bromfenac Sodium | 13 | $3,289 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $2,412 |
| Difluprednate | 15 | $1,492 |
| ValacyclovirValacyclovir Hcl | 14 | $1,140 |
| Brimonidine Tartrate | 14 | $934 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $792 |
| Timolol Maleate | 46 | $345 |
| Gentamicin Sulfate | 31 | $345 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $260 |
| Dorzolamide Hcl | 14 | $207 |
| Promethazine Hcl | 64 | $177 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Southlake
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.